laboratori corp america hldg
valu still attract growth
strategi rais pt
overal think labcorp deliv expect solid underli
result across diagnost covanc overal revenu growth y/i
beat forecast diagnost drove beat pleas adj
ebit came modestli ahead expect labcorp dx deliv beat vs
forecast rev-per-req drive upsid inclus pama
headwind headwind beacon lb off-set contribut
pleas organ volum growth consist
expect open unitedhealth network januari anniversari
head adj ebit beat forecast covanc
net organ growth quot mid-to-high singl digit
modestli forecast consid covanc adj ebit
grew y/i beat forecast add convict
underli growth steadi final ttm book-to-bil improv
q/q impli quarterli book-to-bil around view
strong labcorp repurchas share complet
quarter leverag ttm ebitda expect gener
free cash flow believ compani remain flexibl deploy
capit augment growth
look labcorp initi guidanc bracket expect
total growth expect believ impli organ growth
labcorp continu face pressur pama dx segment
good track record find effici launchpad protect earn growth
ep guidanc repres y/i consist expect
given improv visibl rais price target
continu view labcorp valuat compel context
rel busi mix opportun drive upsid share gain
lh quarterli annual ep usd
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay laboratori corp america hldg
laboratori corp america hldg lh
overweight labcorp good track record
execut led solid organ growth
augment value-enhanc acquisit
time expect labcorp scale advantag across
diagnost drug develop gain share
substanti free cash flow use
augment growth
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay laboratori corp america hldg
overal think labcorp deliv expect solid underli
result across diagnost covanc overal revenu growth y/i beat
forecast diagnost drove beat pleas adj ebit
came modestli ahead expect labcorp dx deliv beat vs
forecast rev-per-req drive upsid inclus pama headwind
headwind beacon lb off-set contribut pleas
organ volum growth consist expect open
unitedhealth network januari anniversari head adj ebit
beat forecast covanc net organ growth quot
mid-to-high singl digit modestli forecast asc-
consid covanc adj ebit grew y/i beat forecast
add convict underli growth steadi final ttm
book-to-bil improv q/q impli quarterli book-to-bil
around view strong labcorp repurchas share
complet quarter leverag ttm ebitda
expect gener free cash flow believ compani
remain flexibl deploy capit augment growth
look labcorp initi guidanc bracket expect total
growth expect believ impli organ growth labcorp
continu face pressur pama dx segment good track record
find effici launchpad protect earn growth ep guidanc
repres growth y/i consist expect
given improv visibl rais price target
continu view labcorp valuat compel context rel
busi mix opportun drive upsid share gain price target
repres adj ep prior pt repres prior
adj ep ebitda basi standard balanc sheet labcorp
current trade ebitda repres discount sum-of-
part valuat labcorp lab busi comp quest trade
ebitda covanc comp basket cro peer trade
believ two potenti catalyst labcorp earn multipl expans
deliv higher covanc growth also potenti initi dividend
would attract broader pool investor stock
barclay laboratori corp america hldg
labcorp valuat comp impli multipl
labcorp initi guidanc bracket expect labcorp expect
revenu growth constant currenc growth expect
estim organ growth forecast overal adjust month
envigo transact labcorp diagnost expect show total growth
includ headwind pama leap day tailwind
includ forecast fx tailwind also assum
includ growth covanc total growth project
includ benefit fx impli constant currenc growth rang
estim includ net tailwind envigo impli organ growth
ep guidanc repres growth y/i
ebitdaev ebitdamarket cap ebitdacharl impli cro average barclay laboratori corp america hldg
labcorp report revenu billion y/i came
forecast includ organ growth vs forecast
acquir growth divest growth net forecast
fx vs model versu model beat predominantli
driven better contribut look compani two segment
labcorp diagnost revenu billion includ organ growth
coupl divest headwind drive overal increas
y/i overal growth came forecast total growth organ
volum increas forecast y/i labcorp
call neg impact manag care lower consum genet
test off-set addit revenu day size
impli underli util quarter view good read
diagnost market environ revenu per requisit increas y/i
exclud divestitur make adjust pama headwind
nonrenew beaconlb florida size
guidanc dx dx dx lb organ organ organ growth barclay laboratori corp america hldg
quarter impli underli rev-per-req stronger note
rev-per-req also impact mix compani call
favor mix help result
covanc revenu billion forecast
gross organ growth size forecast compani ad
exclud pass-through view irrelev core growth net organ
growth mid-to-high singl digit compar organ growth
forecast overal revenu increas y/i gross organ
growth net acquisit contribut off-set fx
ttm book-to-bil improv ttm
believ impli quarterli book-to-bil roughli view
strong note time drive quarterli figur labcorp busi mix
blend toward quicker burn revenu given central lab earli develop
exposur backlog grew y/i
quarterli revenu million organ growth
growth y/i barclay laboratori corp america hldg
note organ reimburs growth adjust fx beacon lb
labcorp adjust mix
covanc deliv revenu billion
forecast gross organ growth size forecast
compani ad exclud pass-through view irrelev core growth
millionsestestestestestestestfisc year end dec labcorp metricstot growth organ growth dx growth acquir total access organ net new weather calendar underli ppa beacon organ lab rev medicar pama overal y/i organ growth barclay laboratori corp america hldg
net organ growth mid-to-high singl digit compar organ
growth forecast overal revenu increas y/i gross organ
growth net acquisit contribut off-set fx ttm
book-to-bil improv ttm
believ impli quarterli book-to-bil roughli view strong
note time drive quarterli figur labcorp busi mix blend toward
quicker burn revenu given central lab earli develop exposur backlog
segment organ growth labcorp
pama repres headwind quarterli lab revenu full-year
impact look labcorp forecast headwind pama
remind implement pama kick largest chang
diagnost reimburs year result confirm belief pama
lead meaning medicar cut time lead period heighten lab industri
consolid pama expect serv headwind compani
medicar revenu anoth financi impact
still meaning yet manag given medicar clf repres
labcorp revenu medicar reimburs chang actual sizabl survey
work interact lab director suggest industri experi period
meaning consolid ultim believ smaller lab outsiz medicar
exposur consolid time either organ inorgan benefit
labcorp quest industri leader
effort broaden hospit lab particip american clinic laboratori
associ acla support legisl known laboratori access
beneficiari lab act recent sign law presid trump part
year end spend packag legisl delay aggreg data
one year order give time hospit outreach
smaller lab get system place submit compliant data would give
applic lab time prepar next round data report
would delay next round cut absenc anoth survey period
medicar rate go base prior pama survey call
medicar cut
organ growth labcorp dxcovanc drug develop barclay laboratori corp america hldg
clf medicar rate cut year
applic laboratori test volum survey
essenc nation lab pursu strategi addit time broaden
pool particip lab improv long-term reimburs
beyond said expect much relief given quest labcorp
repres major volum submit routin code regardless level
hospit particip shown medicar data show quest
labcorp repres anywher volum routin test
code hospit could particip pama survey labcorp quest
would still repres volume-weight median
medicar market share routin volum
adjust ebit ex-amort increas y/i million adj ebit
margin percentag net revenu increas y/i in-lin
estim labcorp diagnost margin declin y/i
covanc drug develop margin improv diagnost adjust
oper incom impact pama million higher personnel cost
cybersecur invest partial off-set launchpad save organ growth
acquisit covanc margin benefit organ demand launchpad save
acquisit partial off-set higher personnel cost
cuttyp laboratori npi report laboratori test volumeperc total report laboratori test offic urgent center hospit inpati panelmetabol panelvitamin barclay laboratori corp america hldg
adj ebit margin segment ex-corpor overhead
sg repres net revenu quarter estim
revenu lower expect ebitda
margin came expect due modestli better cog
higher expect incom equiti invest
sg trend revenu
flow oper came million estim
million cffo repres adjust net incom quarter rel
expect stronger profit off-set lower expect work
capit quarter capital-expenditure million repres net revenu
y/i capit deploy consist million share repurchas
million acquisit labcorp repurchas million share
deploy million toward labcorp exit net debt ebitda
remind labcorp envigo privat close trade preclin
asset appear strateg win-win parti specif labcorp
sg abad debt lab barclay laboratori corp america hldg
acquir envigo non-clin research servic busi envigo acquir labcorp
research model servic busi net-net labcorp agre pay
acquir revenu pro forma basi revenu multipl
estim purchas price also repres ttm ebitda labcorp note
propos transact earn cash accret year one exceed
compani cost capit year math estim would repres around
accret full-year basi prior potenti synergi opportun full
thought transact pleas see report lh preclin trade
envigo strateg win-win
use oper million
flowcapex barclay laboratori corp america hldg
labcorp mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay laboratori corp america hldg
million except per share dataestestestestestestestestfisc year end dec growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
